Pieris Pharmaceuticals (PIRS) Competitors $15.39 -0.62 (-3.87%) (As of 11:00 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PIRS vs. FGEN, CASI, ME, CMRX, CLSD, EPIX, IMAB, PDSB, ONCY, and FBLGShould you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include FibroGen (FGEN), CASI Pharmaceuticals (CASI), 23andMe (ME), Chimerix (CMRX), Clearside Biomedical (CLSD), ESSA Pharma (EPIX), I-Mab (IMAB), PDS Biotechnology (PDSB), Oncolytics Biotech (ONCY), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical preparations" industry. Pieris Pharmaceuticals vs. FibroGen CASI Pharmaceuticals 23andMe Chimerix Clearside Biomedical ESSA Pharma I-Mab PDS Biotechnology Oncolytics Biotech FibroBiologics Pieris Pharmaceuticals (NASDAQ:PIRS) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Which has more risk and volatility, PIRS or FGEN? Pieris Pharmaceuticals has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Is PIRS or FGEN more profitable? Pieris Pharmaceuticals has a net margin of -39.71% compared to FibroGen's net margin of -67.66%. FibroGen's return on equity of 0.00% beat Pieris Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Pieris Pharmaceuticals-39.71% -80.93% -59.55% FibroGen -67.66%N/A -36.17% Does the MarketBeat Community favor PIRS or FGEN? FibroGen received 65 more outperform votes than Pieris Pharmaceuticals when rated by MarketBeat users. Likewise, 60.71% of users gave FibroGen an outperform vote while only 60.30% of users gave Pieris Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPieris PharmaceuticalsOutperform Votes27860.30% Underperform Votes18339.70% FibroGenOutperform Votes34360.71% Underperform Votes22239.29% Which has preferable earnings & valuation, PIRS or FGEN? Pieris Pharmaceuticals has higher earnings, but lower revenue than FibroGen. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPieris Pharmaceuticals$42.81M0.47-$24.54M-$12.10-1.27FibroGen$147.75M0.25-$284.23M-$1.23-0.30 Does the media refer more to PIRS or FGEN? In the previous week, FibroGen had 3 more articles in the media than Pieris Pharmaceuticals. MarketBeat recorded 5 mentions for FibroGen and 2 mentions for Pieris Pharmaceuticals. FibroGen's average media sentiment score of 0.80 beat Pieris Pharmaceuticals' score of 0.21 indicating that FibroGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pieris Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroGen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer PIRS or FGEN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pieris Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders hold more shares of PIRS or FGEN? 40.1% of Pieris Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 6.4% of Pieris Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryFibroGen beats Pieris Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get Pieris Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PIRS vs. The Competition Export to ExcelMetricPieris PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.32M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio-1.274.9791.2813.60Price / Sales0.47371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book1.2510.306.906.33Net Income-$24.54M$153.61M$118.83M$225.93M7 Day Performance-3.51%-1.73%-1.92%-0.96%1 Month Performance-8.39%-7.26%-3.75%1.06%1 Year Performance-11.35%31.10%31.37%26.59% Pieris Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PIRSPieris Pharmaceuticals1.6293 of 5 stars$15.39-3.9%N/A-10.4%$20.32M$42.81M-1.27140Analyst UpgradeNews CoverageFGENFibroGen2.4563 of 5 stars$0.37+5.3%N/A-33.8%$37.12M$147.75M-0.28486Analyst RevisionGap DownCASICASI Pharmaceuticals3.802 of 5 stars$5.25-0.2%$6.00+14.3%+0.4%$81.17M$33.88M0.00180ME23andMe1.237 of 5 stars$3.30+4.8%$9.40+184.8%-82.6%$80.88M$219.64M-0.13770CMRXChimerix4.521 of 5 stars$0.90+2.1%$8.50+845.7%-12.0%$80.84M$320,000.000.0072Analyst ForecastCLSDClearside Biomedical3.0181 of 5 stars$1.05flat$5.33+407.9%+8.1%$79.63M$8.23M-2.3330Analyst RevisionEPIXESSA Pharma2.7977 of 5 stars$1.79+3.5%$11.67+551.8%-68.0%$79.42MN/A-2.7950IMABI-Mab2.5473 of 5 stars$0.94-4.0%$8.00+750.2%-37.6%$76.63M$3.89M0.0034PDSBPDS Biotechnology1.8427 of 5 stars$2.04+0.5%$12.33+504.6%-67.9%$76.32MN/A0.0020ONCYOncolytics Biotech1.2173 of 5 stars$0.99-0.9%$4.00+304.0%-37.2%$76.30MN/A0.0030Analyst RevisionFBLGFibroBiologics1.7478 of 5 stars$2.20-1.8%$12.00+445.5%N/A$76.25MN/A0.0010 Related Companies and Tools Related Companies FibroGen Alternatives CASI Pharmaceuticals Alternatives 23andMe Alternatives Chimerix Alternatives Clearside Biomedical Alternatives ESSA Pharma Alternatives I-Mab Alternatives PDS Biotechnology Alternatives Oncolytics Biotech Alternatives FibroBiologics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PIRS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PIRS Stock Alerts